Project 3 of the CREATE Pharmacogenetics Research Network will characterize polymorphisms in members of the pathways regulating drug activity in Caucasians, Hispanic, Asian, and African American populations. This project stems from the clear evidence in quantitative and qualitative differences in clinically relevant polymorphisms between ethnic groups. As both Washington University and University of Southern California serve diverse patient population, the influence of ethnicity of variant frequency is of direct relevance to these centers.
The specific aims of this project are: 1) Characterize genotype and allele frequency of drug pathway variants in Caucasian, Hispanic, Asian and African American populations 2) Confirm that the variants of interest are an inherited genotype 3) Describe gene flow for variants within the drug pathways This will be accomplished by analysis of genotype in 300 individuals from each of the four ethnic groups. Assessment of DNA from CEPH Reference Families will be used to confirm that the variant of interest is an inherited genotype. Population genetics models will also be used to define whether the pathway variants have been acquired in a systematic fashion or whether each gene has recombination as an isolated, unrelated event to the other genes in the pathway. Together these approaches will provide useful data on the variants of interest and important information of potential predictive impact for using pharmacogenetics to optimize therapy in all populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01GM063340-02
Application #
6659300
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2002-08-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Marsh, Sharon; King, Cristi R; Van Booven, Derek J et al. (2015) Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 16:441-8
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Hariani, Gunjan D; Lam, Ernest T; Lam, Ernest J et al. (2014) Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes 7:360
McWhinney-Glass, Sarah; Winham, Stacey J; Hertz, Daniel L et al. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 19:5769-76
Trammel, Morgan; Roederer, Mary; Patel, Jai et al. (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 15:276-85
Motsinger-Reif, Alison A; Jorgenson, Eric; Relling, Mary V et al. (2013) Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 23:383-94
Crowley, James J; Kim, Yunjung; Szatkiewicz, Jin Peng et al. (2012) Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 23:322-35
He, Y J; McLeod, H L (2012) Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther 92:412-4
Hoskins, Janelle M; Ong, Pei-Shi; Keku, Temitope O et al. (2012) Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 7:e41954
Crowley, J J; Adkins, D E; Pratt, A L et al. (2012) Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J 12:147-55

Showing the most recent 10 out of 181 publications